Tyrosine kinase receptor status in endometrial stromal sarcoma: An immunohistochemical and genetic-molecular analysis

International Journal of Gynecological Pathology

Volumn 31, Issue 6, 2012, Pages 570-579

  Cossu Rocca, Paolo ^b   Contini, Marcella ^a   Uras, Maria Gabriela ^b   Muroni, Maria Rosaria ^b   Pili, Francesca ^a   Carru, Ciriaco ^b   Bosincu, Luisanna ^b   Massarelli, Giovannino ^b   Nogales, Francisco F ^c   De Miglio, Maria Rosaria ^b  

^a Surgical Pathology Unit   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

ABL; EGFR; Endometrial stromal sarcoma; Targeted therapies; Tyrosine kinase receptors

Indexed keywords

ABELSON KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEM CELL FACTOR; TYROSINE KINASE RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM SARCOMA; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SARCOMA, ENDOMETRIAL STROMAL;

EID: 84867400448     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31824fe289     Document Type: Article

References (40)

1. Kurihara S, Oda Y, Ohishi Y, et al. Endometrial stromal sarcomas and related high-grade sarcomas: Immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol 2008;32:1228-38.
2. Hendrickson MR, Tavassoli FA, Kempson RL, et al. Mesenchymal tumors and related lesions. In: Tavassoli FA, Devilee P, eds. World Health Organisation Classification of Tumors. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. Lyon: IARC Press; 2003:233-44.
3. Xue WC, Cheung AN. Endometrial stromal sarcoma of uterus. Best Pract Res Clin Obstet Gynaecol 2011;25:719-32.
4. Nam JH, Park JY. Update on treatment of uterine sarcoma. Curr Opin Obstet Gynecol 2010;22:36-42.
5. Seddon BM, Davda R. Uterine sarcomas - recent progress and future challenges. Eur J Radiol 2011;78:30-40.
6. Valduvieco I, Rovirosa A, Colomo L, et al. Endometrial stromal sarcoma. Is there a place for radiotherapy? Clin Transl Oncol 2010;12:226-30.
7. Dupont NC, Disaia PJ. Recurrent endometrial stromal sarcoma: Treatment with a progestin and gonadotropin releasing hormone agonist. Sarcoma 2010. [Epub June 10, 2010].
8. Nakayama K, Ishikawa M, Nagai Y, et al. Prolonged longterm survival of low-grade endometrial stromal sarcoma patients with lung metastasis following treatment with medroxyprogesterone acetate. Int J Clin Oncol 2010;15:179-83.
9. Salvatierra A, Tarrats A, Gomez C, et al. A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate. Gynecol Oncol 2006;101:545-7.
10. Mitsuhashi T, Nakayama M, Sakurai S, et al. KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate. Ann Diagn Pathol 2007;11:49-54.
11. Kalender ME, Sevinc A, Yilmaz M, et al. Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma. Cancer Chemother Pharmacol 2009;63:555-9.
12. De Miglio MR, Mura A, Uras MG, et al. High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples. Diagn Mol Pathol 2010;19:201-8.
13. Moinfar F, Gogg-Kamerer M, Sommersacher A, et al. Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): Potential basis for a new therapeutic approach. Am J Surg Pathol 2005;29:485-9.
14. Gotoh N. Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors. Int J Clin Exp Pathol 2011;4:403-9.
15. Chang JW, Liu HP, Hsieh MH, et al. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in nonsmall cell lung cancers: A chromogenic in situ hybridization study of 182 patients. Lung Cancer 2008;61:328-39.
16. Tsiambas E, Manaios L, Papanikolopoulos C, et al. Chromogenic in situ hybridization analysis of Epidermal Growth Factor Receptor gene/chromosome 7 numerical aberrations in hepatocellular carcinoma based on tissue microarrays. Pathol Oncol Res 2009;15:511-20.
17. Pectasides E, Rampias T, Kountourakis P, et al. Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma. Clin Cancer Res 2011;17:2947-54.
18. Cossu Rocca P, Pili F, Festa A, et al. Analysis of EGFR status in endometrial stromal sarcoma. Lab Invest 2007;87:193A-4A.
19. Zandi R, Larsen AB, Andersen P, et al. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007;19:2013-23.
20. Bache KG, Slagsvold T, Stenmark H. Defective downregulation of receptor tyrosine kinases in cancer. EMBO J 2004;23:2707-12.
21. Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
22. Caudell JJ, Deavers MT, Slomovitz BM, et al. Imatinib mesylate (gleevec) - targeted kinases are expressed in uterine sarcomas. Appl Immunohistochem Mol Morphol 2005;13: 167-70.
23. Erdogan G, Bassorgun CI, Pestereli HE, et al. C-kit protein expression in uterine and ovarian mesenchymal tumours. APMIS 2007;115:204-9.
24. Geller MA, Argenta P, Bradley W, et al. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. Gynecol Oncol 2004;95:632-6.
25. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002;117:188-93.
26. Klein WM, Kurman RJ. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int J Gynecol Pathol 2003;22:181-4.
27. Liegl B, Gully C, Reich O, et al. Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations. Histopathology 2007;50:448-52.
28. Wang L, Felix JC, Lee JL, et al. The proto-oncogene c-kit is expressed in leiomyosarcomas of the uterus. Gynecol Oncol 2003;90:402-6.
29. Yantiss RK, Clement PB, Young RH. Neoplastic and preneoplastic changes in gastrointestinal endometriosis: A study of 17 cases. Am J Surg Pathol 2000;24:513-24.
30. Adams SF, Hickson JA, Hutto JY, et al. PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol 2007;104:524-8.
31. Nakayama M, Mitsuhashi T, Shimizu Y, et al. Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region. Int J Gynecol Pathol 2006;25:70-6.
32. Rushing RS, Shajahan S, Chendil D, et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol Oncol 2003;91:9-14.
33. Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol 2006;23:91-102.
34. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008;53:245-66.
35. Gaiger A, Henn T, Horth E, et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995;86:2371-8.
36. Cheng X, Yang G, Schmeler KM, et al. Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol 2011;121:323-7.
37. Chandra HS, Heisterkamp NC, Hungerford A, et al. Philadelphia Chromosome Symposium: Commemoration of the 50th anniversary of the discovery of the Ph chromosome. Cancer Genet 2011;204:171-9.
38. Leonetti F, Stefanachi A, Nicolotti O, et al. BCR-ABL inhibitors in chronic myeloid leukemia: Process chemistry and biochemical profile. Curr Med Chem 2011;18:2943-59.
39. Sandberg AA. The cytogenetics and molecular biology of endometrial stromal sarcoma. Cytogenet Genome Res 2007;118:182-9.
40. Weiss FU, Daub H, Ullrich A. Novel mechanisms of RTK signal generation. Curr Opin Genet Dev 1997;7:80-6.